Technical Analysis for ANNX - Annexon, Inc.

Grade Last Price % Change Price Change
F 22.955 -1.27% -0.30
ANNX closed down 6.74 percent on Monday, April 12, 2021, on 64 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical ANNX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -1.27%
Oversold Stochastic Weakness -1.27%
Doji - Bullish? Reversal -7.92%
Wide Bands Range Expansion -7.92%
Oversold Stochastic Weakness -7.92%
Narrow Range Bar Range Contraction -8.73%
NR7 Range Contraction -8.73%
Stochastic Reached Oversold Weakness -8.73%
Inside Day Range Contraction -8.73%
Wide Bands Range Expansion -8.73%
Older End-of-Day Signals for ANNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
60 Minute Opening Range Breakdown about 5 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Annexon, Inc. Description

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Eye Immune System Monoclonal Antibody Antibody Ophthalmic Biomarker Degenerative Disease Autoimmunity Platform Technology Neurodegenerative Disorders Complement System Intravitreal Administration

Is ANNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 38.01
52 Week Low 15.33
Average Volume 182,469
200-Day Moving Average 0.00
50-Day Moving Average 28.43
20-Day Moving Average 28.11
10-Day Moving Average 25.58
Average True Range 2.42
ADX 21.0
+DI 13.63
-DI 25.21
Chandelier Exit (Long, 3 ATRs ) 28.72
Chandelier Exit (Short, 3 ATRs ) 30.44
Upper Bollinger Band 34.49
Lower Bollinger Band 21.74
Percent B (%b) 0.12
BandWidth 45.37
MACD Line -1.42
MACD Signal Line -0.89
MACD Histogram -0.5322
Fundamentals Value
Market Cap 887.16 Million
Num Shares 38.2 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -103.70
Price-to-Sales 0.00
Price-to-Book 2.60
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.67
Resistance 3 (R3) 25.91 25.34 25.26
Resistance 2 (R2) 25.34 24.73 25.22 25.13
Resistance 1 (R1) 24.30 24.35 24.02 24.06 24.99
Pivot Point 23.73 23.73 23.59 23.61 23.73
Support 1 (S1) 22.69 23.12 22.41 22.45 21.51
Support 2 (S2) 22.12 22.74 22.00 21.37
Support 3 (S3) 21.08 22.12 21.24
Support 4 (S4) 20.84